San Marino, CA (PRWEB) February 1, 2011 —
Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, (Pinksheets: VRAL) and published their initial report today. The report is available on the company’s website at http://www.viralgenetics.com/investors/press-releases/Research_2.0_Report_Feb1_2011.pdf and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com. Research 2.0 is pioneering a new “open professional” model of investment research which gives companies a direct path to quality independent institutional research coverage via an annual retainer and making that research broadly available to all potential investors on the Internet and in open social and professional online networks.
“We’ll let the report and the Research 2.0 analysts speak for themselves, but suffice it to say that we’re very happy to reach a new audience with a professional analysis and evaluation of the company at the same time that we’ve successfully transitioned from a preclinical to clinical stage biotech company,” said Viral Genetics CEO Haig Keledjian.
Research 2.0’s principals have over 50 years combined experience in traditional investment banking research and portfolio management, including the managing of a five hundred million dollar biotech investment management fund. The firm provides research coverage and advisory services to over two-dozen small, technology-focused public and private companies in a variety of sectors including life sciences, software, cloud computing and other technologies. Their research reports on clients are available through FactSet, CapitalIQ, and TheMarkets.com, as well as through subscription services. Additionally, over 12,000 individual investors, media, investment professionals and others subscribe to the Research 2.0 blog where founder and CEO, Kris Tuttle, writes additional updates and more informal notes about clients, the markets and other topics, available at http://blog.research2zero.com and syndicated to http://www.seekingalpha.com.
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at http://www.viralgenetics.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Genetics’ drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
Haig Keledjian, Viral Genetics
T: (626) 334-5310